Literature DB >> 27622053

Th22 cells control colon tumorigenesis through STAT3 and Polycomb Repression complex 2 signaling.

Danfeng Sun1, Yanwei Lin1, Jie Hong2, Haoyan Chen2, Nisha Nagarsheth3, Dongjun Peng4, Shuang Wei4, Emina Huang5, Jingyuan Fang2, Ilona Kryczek4, Weiping Zou6.   

Abstract

Th22 cells traffic to and retain in the colon cancer microenvironment, and target core stem cell genes and promote colon cancer stemness via STAT3 and H3K79me2 signaling pathway and contribute to colon carcinogenesis. However, whether Th22 cells affect colon cancer cell proliferation and apoptosis remains unknown. We studied the interaction between Th22 cells and colon cancer cells in the colon cancer microenvironment. Colon cancer proliferation was examined by flow cytometry analysis and H(3) thymidine incorporation. Cell cycle related genes were quantified by real-time PCR and Western blotting. We transfected colon cancer cells with lentiviral vector encoding specific gene shRNAs and used chromatin immunoprecipitation (ChIP) assay to determine the genetic signaling involved in interleukin (IL)-22-mediated colon cancer cell proliferation. We showed that Th22 cells released IL-22 and stimulated colon cancer proliferation. Mechanistically, IL-22 activated STAT3, and subsequently STAT3 bound to the promoter areas of the Polycomb Repression complex 2 (PRC2) components SUZ12 and EED, and stimulated the expression of PRC2. Consequently, the activated PRC2 catalyzed the promoters of the cell cycle check-point genes p16 and p21, and inhibited their expression through H3K27me3-mediated histone methylation, and ultimately caused colon cancer cell proliferation. Bioinformatics analysis revealed that the levels of IL-22 expression positively correlated with the levels of genes controlling cancer proliferation and cell cycling in colon cancer. In addition to controlling colon cancer stemness, Th22 cells support colon carcinogenesis via affecting colon cancer cell proliferation through a distinct histone modification.

Entities:  

Keywords:  Colon cancer; IL-22; PRC2; STAT3; Th22

Year:  2015        PMID: 27622053      PMCID: PMC5007968          DOI: 10.1080/2162402X.2015.1082704

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  29 in total

Review 1.  The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3.

Authors:  Ru Cao; Yi Zhang
Journal:  Curr Opin Genet Dev       Date:  2004-04       Impact factor: 5.578

2.  S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites.

Authors:  Jiehui Deng; Yong Liu; Heehyoung Lee; Andreas Herrmann; Wang Zhang; Chunyan Zhang; Shudan Shen; Saul J Priceman; Maciej Kujawski; Sumanta K Pal; Andrew Raubitschek; Dave S B Hoon; Stephen Forman; Robert A Figlin; Jie Liu; Richard Jove; Hua Yu
Journal:  Cancer Cell       Date:  2012-05-15       Impact factor: 31.743

Review 3.  The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling.

Authors:  Hergen Spits; James P Di Santo
Journal:  Nat Immunol       Date:  2010-11-28       Impact factor: 25.606

4.  Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors.

Authors:  Wenyu Yu; Emma J Chory; Amy K Wernimont; Wolfram Tempel; Alex Scopton; Alexander Federation; Jason J Marineau; Jun Qi; Dalia Barsyte-Lovejoy; Joanna Yi; Richard Marcellus; Roxana E Iacob; John R Engen; Carly Griffin; Ahmed Aman; Erno Wienholds; Fengling Li; Javier Pineda; Guillermina Estiu; Tatiana Shatseva; Taraneh Hajian; Rima Al-Awar; John E Dick; Masoud Vedadi; Peter J Brown; Cheryl H Arrowsmith; James E Bradner; Matthieu Schapira
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

5.  Role of STAT3 and vitamin D receptor in EZH2-mediated invasion of human colorectal cancer.

Authors:  Yan-Wei Lin; Lin-Lin Ren; Hua Xiong; Wan Du; Ya-Nan Yu; Tian-Tian Sun; Yu-Rong Weng; Zhen-Hua Wang; Ji-Lin Wang; Ying-Chao Wang; Yun Cui; Dan-Feng Sun; Ze-Guang Han; Nan Shen; Weiping Zou; Jie Xu; Hao-Yan Chen; Weibiao Cao; Jie Hong; Jing-Yuan Fang
Journal:  J Pathol       Date:  2013-07       Impact factor: 7.996

6.  Antiapoptotic activity of autocrine interleukin-22 and therapeutic effects of interleukin-22-small interfering RNA on human lung cancer xenografts.

Authors:  Weici Zhang; Yongyan Chen; Haiming Wei; Chaogu Zheng; Rui Sun; Jian Zhang; Zhigang Tian
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

7.  Expression of interleukin-22/STAT3 signaling pathway in ulcerative colitis and related carcinogenesis.

Authors:  Lian-Zhen Yu; Hai-Yang Wang; Shu-Ping Yang; Zhi-Ping Yuan; Fang-Yuan Xu; Chao Sun; Rui-Hua Shi
Journal:  World J Gastroenterol       Date:  2013-05-07       Impact factor: 5.742

8.  Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation.

Authors:  Karam Kim; Garam Kim; Jin-Young Kim; Hyo Jeong Yun; Sung-Chul Lim; Hong Seok Choi
Journal:  Carcinogenesis       Date:  2014-02-11       Impact factor: 4.944

9.  IL-22 increases the innate immunity of tissues.

Authors:  Kerstin Wolk; Stefanie Kunz; Ellen Witte; Markus Friedrich; Khusru Asadullah; Robert Sabat
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

10.  GSEA-P: a desktop application for Gene Set Enrichment Analysis.

Authors:  Aravind Subramanian; Heidi Kuehn; Joshua Gould; Pablo Tamayo; Jill P Mesirov
Journal:  Bioinformatics       Date:  2007-07-20       Impact factor: 6.937

View more
  17 in total

1.  Significant association of EED promoter hypomethylation with colorectal cancer.

Authors:  Xiuru Ying; Ranran Pan; Jie Zhong; Boyi Wu; Yuting Jiang; Jieer Ying; Cong Zhou; Jie Dai; Shuangying Zhao; Yinan Shen; Wei Zhang; Shiwei Duan
Journal:  Oncol Lett       Date:  2019-06-04       Impact factor: 2.967

Review 2.  Biological and pathological activities of interleukin-22.

Authors:  Mirna Perusina Lanfranca; Yanwei Lin; Jingyuan Fang; Weiping Zou; Timothy Frankel
Journal:  J Mol Med (Berl)       Date:  2016-02-29       Impact factor: 4.599

Review 3.  Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy.

Authors:  Nisha Nagarsheth; Max S Wicha; Weiping Zou
Journal:  Nat Rev Immunol       Date:  2017-05-30       Impact factor: 53.106

Review 4.  Reparative T lymphocytes in organ injury.

Authors:  Franco R D'Alessio; Johanna T Kurzhagen; Hamid Rabb
Journal:  J Clin Invest       Date:  2019-07-01       Impact factor: 14.808

Review 5.  Role of IL-22 in intestinal microenvironment and potential targeted therapy through diet.

Authors:  Peiying Wang; Wing Keung Chan; Jiming Wang; Zhouxin Yang; Youwei Wang
Journal:  Immunol Res       Date:  2022-09-29       Impact factor: 4.505

6.  IL22 Promotes Kras-Mutant Lung Cancer by Induction of a Protumor Immune Response and Protection of Stemness Properties.

Authors:  Nasim Khosravi; Mauricio S Caetano; Amber M Cumpian; Nese Unver; Cynthia De la Garza Ramos; Oscar Noble; Soudabeh Daliri; Belinda J Hernandez; Berenice A Gutierrez; Scott E Evans; Samir Hanash; Andrei M Alekseev; Yi Yang; Seon Hee Chang; Roza Nurieva; Humam Kadara; Jichao Chen; Edwin J Ostrin; Seyed Javad Moghaddam
Journal:  Cancer Immunol Res       Date:  2018-05-15       Impact factor: 11.151

Review 7.  Regulation of TH17 Cells and Associated Cytokines in Wound Healing, Tissue Regeneration, and Carcinogenesis.

Authors:  Leonie Brockmann; Anastasios D Giannou; Nicola Gagliani; Samuel Huber
Journal:  Int J Mol Sci       Date:  2017-05-11       Impact factor: 5.923

8.  The Imbalance between Foxp3+Tregs and Th1/Th17/Th22 Cells in Patients with Newly Diagnosed Autoimmune Hepatitis.

Authors:  Ma Liang; Zhang Liwen; Zhuang Yun; Ding Yanbo; Chen Jianping
Journal:  J Immunol Res       Date:  2018-06-27       Impact factor: 4.818

Review 9.  Chemokine Heterocomplexes and Cancer: A Novel Chapter to Be Written in Tumor Immunity.

Authors:  Gianluca D'Agostino; Valentina Cecchinato; Mariagrazia Uguccioni
Journal:  Front Immunol       Date:  2018-09-25       Impact factor: 7.561

10.  DNA methylation-regulated and tumor-suppressive roles of miR-487b in colorectal cancer via targeting MYC, SUZ12, and KRAS.

Authors:  Xu Chen; Zhi-Feng Lin; Wen-Jin Xi; Wei Wang; Dan Zhang; Fan Yang; Yu-Fang Li; Yi Huo; Tian-Ze Zhang; Yi-Hong Jiang; Wei-Wei Qin; An-Gang Yang; Tao Wang
Journal:  Cancer Med       Date:  2019-02-21       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.